You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and primary pulmonary hypertension
SBC: FANNIN PARTNERS LLC Topic: FDAPROJECT SUMMARY Over 3 million people are diagnosed with heart failure with preserved ejection fraction (HFpEF) annually in the US. Despite its high incidence, HFpEF is often not diagnosed until late in its course because the primary symptom, dyspnea, is common to other conditions including atrial fibrillation, lung disease, and/or obesity. Therefore, doctors order multiple examinations including ...
SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration -
Adaptive Mechanical Models for Realistic Radiation Sterilization Simulations
SBC: TRIPLE RING TECHNOLOGIES INC Topic: FDAProject Summary Medical Device development has an underlying paradigm to reduce risk early in the development cycle. Developers are using computational tools such as finite element analysis to mitigate risks from thermal loads, mechanical stresses etc. There is one exception to this paradigm: sterilization validation. Sterilization validation is addressed late in the development cycle as an actual ...
SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration -
Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment
SBC: En Solucion Inc Topic: FDARecent foodborne illness outbreaks traced to contaminated field harvesting equipment have highlighted the need for incorporating improved sanitization practices at the time of harvest. Field- harvested specialty crops represent 50% of the top ten foods linked to major recalls and outbreaks over the past five years. Proper sanitization of outdoor harvest equipment is made complicated by operational ...
SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration -
A Mobile-Delivered Personalized Feedback Intervention for Black Individuals who Engage in Hazardous Drinking
SBC: HEALTH BEHAVIOR SOLUTIONS INC Topic: 400PROJECT SUMMARY/ABSTRACT Black persons are the second largest racial minority group in the United States (US) and experience striking health disparities, particularly in terms of hazardous drinking and co-occurring elevated anxiety. The co- occurrence of these risk factors contributes to worse physical/mental health outcomes among Black individuals. Few interventions to date have targeted hazardou ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Chromosomal aberration detection in FFPE tissue using proximity ligation sequencing
SBC: PHASE GENOMICS, INC. Topic: NCIABSTRACT The detection of chromosomal aberrations is a frontline diagnostic for the spectrum of blood neoplasms. Chromosomal aberrations, such as translocations, inversions, deletions and insertions, have been historically identified using cytogenetic methods or more recently through application of long read sequencing or optical mapping technologies. These methods have been less applicable in sol ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
SBC: Sarya, LLC Topic: 102PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
SBC: RIP ROAD, INC. Topic: NIAProject SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
SBC: Stemsynergy Therapeutic Topic: 102PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Ambulatory cryocooling therapy device
SBC: NANOHMICS INC Topic: NIAMSPI: Savoy Project Summary Tissue protection following injury begins with shutting down vasodilation and limiting subsequent swelling through the application of cold. In many cases, the cold comes in the form of bags of ice or frozen cold packs, or commercial cooling products such ice packs or ice pack holding limb wraps. In others it may be via a chilled water circulator device, for example the Po ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health